Page 1753 - Williams Hematology ( PDFDrive )

1728 Part XI: Malignant Lymphoid Diseases Chapter 106: Essential Monoclonal Gammopathy 1729

35. Wallin A, Larsson SC: Body mass index and risk of multiple myeloma: A meta-analysis 64. O’Connor ML, Rice DT, Buss DH, Muss HB: Immunoglobulin D benign monoclonal
of prospective studies. Eur J Cancer 47:1606, 2011. gammopathy. Cancer 68:611, 1991.
36. Hofmann JN, Moore SC, Lim U, et al: Body mass index and physical activity at different 65. Kinoshita K, Nagai H, Murate T, et al: IgD monoclonal gammopathy of undetermined
ages and risk of multiple myeloma in the NIH-AARP diet and health study. Am J Epi- significance. Int J Hematol 65:169, 1997.
demiol 177:776, 2013. 66. Galeazzi M, Frezzotti A, Paladini C, et al: A case of monoclonal gammopathy of
37. Fonesca R, Bailey RJ, Ahmann GJ, et al: Genomic abnormalities in monoclonal gam- undetermined significance (MGUS): Type IgD-lambda. Clin Chem Lab Med 51:e123,
mopathy of undetermined significance. Blood 100:1417, 2002. 2013.
38. Zandecki M, Lai JL, Genevieve F, et al: Several cytogenetic subclones may be identi- 67. Imhof JW, Balliux RE, Mul NA, Poen H: Monoclonal and diclonal gamma-pathies. Acta
fied within plasma cells from patients with monoclonal gammopathy of undetermined Med Scand 179(Suppl 455):102, 1966.
significance both at diagnosis and during the indolent course of the disease. Blood 68. Jensen K, Jensen B, Olesen H: Three M-components in serum from an apparently
90:3682, 1997. healthy person. Scand J Haematol 4:485, 1967.
39. Avet-Loiseau H, Facon T, Daviet A, et al: 14q32 translocations and monosomy 13 69. Kyle RA, Robinson RA, Katzmann JA: The clinical aspects of biclonal gammopathies:
observed in monoclonal gammopathy of undetermined significance delineate a mul- Review of 57 cases. Am J Med 71:999, 1981.
tistep process for the oncogenesis of multiple myeloma. Cancer Res 59:4546, 1999. 70. Riddell S, Traczyk Z, Paraskevas F, Israels LG: The double gammopathies: Clinical and
40. Königsberg R, Ackermann J, Kaufmann H, et al: Deletions of chromosome 13q in immunological studies. Medicine (Baltimore) 65:135, 1986.
monoclonal gammopathy of undetermined significance. Leukemia 14:1975, 2000. 71. Kyle RA, Greipp PR: “Idiopathic” Bence Jones proteinuria. N Engl J Med 306:564, 1982.
41. Schilling G, Dierlamm J, Hossfeld DK: Prognostic impact of cytogenetic aberrations in 72. Jenner E: Serum free light chains in clinical laboratory diagnostics. Clin Chim Acta
patients with multiple myeloma or monoclonal gammopathy of unknown significance. 427:15, 2014.
Hematol Oncol 23:102, 2005. 73. Hill PG, Forsyth JM, Rai B, Mayne S: Serum free light chains: An alternative to the urine
42. Brousseau M, Leleu X, Gerard J, et al: Hyperdiploidy is a common finding in monoclo- Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem 52:1743,
nal gammopathy of undetermined significance and monosomy 13 is restricted to these 2006.
hyperdiploid patients. Clin Cancer Res 13:6026, 2007. 74. Katzmann JA, Dispenzieri A, Kyle RA, et al: Elimination of the need for urine studies
43. Avet-Loiseau H, Li J-Y, Morineau N: Monosomy 13 is associated with the transition of in the screening algorithm for monoclonal gammopathies by using serum immunofix-
monoclonal gammopathy of undetermined significance to multiple myeloma. Blood ation and free light chain assays. Mayo Clin Proc 81:1575, 2006.
94:2583, 1999. 75. Jagannath S: Value of serum free light chain testing for the diagnosis and monitoring of
44. Bernasconi P, Cavigliano PM, Boni M, et al: Long-term follow up with conventional monoclonal gammopathies in hematology. Clin Lymphoma Myeloma 7:518, 2007.
cytogenetics and band 13q14 interphase/metaphase in situ hybridization monitoring 76. Beetham R, Wassell J, Wallage MJ, et al: Can serum free light chains replace urine elec-
in monoclonal gammopathies of undetermined significance. Br J Haematol 118:545, trophoresis in the detection of monoclonal gammopathies? Ann Clin Biochem 44:516,
2002. 2007.
45. Rasillo A, Tabernero MD, Sanchez ML, et al: Fluorescence in situ hybridization analysis 77. Murray DL, Seningen JL, Dispenzieri A, et al: Laboratory persistence and clinical pro-
of aneuploidization patterns in monoclonal gammopathy of undetermined significance gression of small monoclonal abnormalities. Am J Clin Pathol 138:609, 2012.
versus multiple myeloma and plasma cell leukemia. Cancer 97:601, 2003. 78. Barnidge DR, Dasari S, Botz CM, et al: Using mass spectrometry to monitor mono-
46. Zojer N, Ludwig H, Fiegi M, et al: Patterns of somatic mutations in VH genes reveal clonal immunoglobulins in patients with a monoclonal gammopathy. J Proteome Res
pathways of clonal transformations from MGUS to multiple myeloma. Blood 101:4137, 13:1419, 2014.
2003. 79. Mangiacavalli S, Cocito F, Pochintesta L, et al: Monoclonal gammopathy of undeter-
47. Lloveras E, Sole F, Florensa L, et al: Contribution of cytogenetics and in situ hybrid- mined significance: A new proposal of workup. Eur J Haematol 91:356, 2013.
ization to the study of monoclonal gammopathy of undetermined significance. Cancer 80. Rajan AM, Rajkumar SV. Diagnostic evaluation of monoclonal gammopathy of unde-
Genet Cytogenet 132:25, 2002. termined significance. Eur J Haematol 91:561, 2013.
48. Landgren O, Kyle RA, Pfeiffer RM, et al: Monoclonal gammopathy of undetermined 81. Kay NE, Gordon LI, Douglas SD: Autoimmune hemolytic anemia in association with
significance (MGUS) consistently precedes multiple myeloma: A prospective study. monoclonal IgM(kappa) with anti-i activity. Am J Med 64:845, 1978.
Blood 113:5412, 2009. 82. Lamboley V, Zabraniecki L, Sie P, et al: Myeloma and monoclonal gammopathy of
49. Weiss BM, Abadie J, Verma P, et al: A monoclonal gammopathy precedes multiple mye- uncertain significance associated with acquired von Willebrand’s syndrome. Seven new
loma in most patients. Blood 113:5418, 2009. cases with a literature review. Joint Bone Spine 69:62, 2002.
50. Davies FE, Dring AM, Li C, et al: Insights into the multistep transformation of MGUS 83. Agarwal N, Klix MM, Burns CP: Successful management with intravenous immuno-
to myeloma using microarray expression analysis. Blood 102:4504, 2003. globulins of acquired von Willebrand disease associated with monoclonal gammopathy
51. Zhan F, Hardin J, Kordesmeier B, et al: Global gene expression profiling of multiple of undetermined significance. Ann Intern Med 6:141:83, 2004.
myeloma, monoclonal gammopathy of undetermined significance, and normal bone 84. Yujiri T, Nakamura Y, Oota I, et al: Acquired von Willebrand syndrome associated with
marrow plasma cells. Blood 99:1745, 2002. monoclonal gammopathy of undetermined significance. Ann Hematol 93:1427, 2014.
52. Zwick C, Held G, Auth M, et al: Over one-third of African-American MGUS and mul- 85. Nocente R, Cammarota G, Gentiloni Silveri N, et al: A case of Sweet’s syndrome asso-
tiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal ciated with monoclonal immunoglobulin of IgG-lambda type and p-ANCA positivity.
dominantly inherited risk factor for MGUS/MM. Int J Cancer 135:934, 2014. Panminerva Med 44:149, 2002.
53. Weinhold N, Johnson DC, Rawstron AC, et al: Inherited genetic susceptibility to mono- 86. Carrington PA, Walsh SE, Houghton JB: Benign paraproteinemia and immune neutro-
clonal gammopathy of unknown significance. Blood 123:2513, 2014. penia. Clin Lab Haematol 2:407, 1989.
54. Xu L, Hunter ZR, Yang G, et al: MYD88 L265P in Waldenström macroglobulinemia, 87. Gabriel DA, Carr ME, Cook L, Roberts HR: Spontaneous antithrombin in a patient
immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative with benign paraprotein. Am J Hematol 25:85, 1987.
disorders using conventional and quantitative allele-specific polymerase chain reaction. 88. Sluiter WJ, Marrink J, Houwen B: Monoclonal gammopathy with an insulin binding
Blood 121:2051, 2013. IgG(K) M-component, associated with severe hypoglycaemia. Br J Haematol 62:679,
55. Xu L, Hunter ZR, Yang G, et al: Detection of MYD88 L265P in peripheral blood of 1986.
patients with Waldenström’s macroglobulinemia and IgM monoclonal gammopathy of 89. Wasada T, Egueli Y, Takayama S, et al: Insulin autoimmune syndrome associated with
undetermined significance. Leukemia 28:1698, 2014. benign monoclonal gammopathy. Diabetes Care 12:147, 1989.
56. Radl J, Hollander CF: Homogeneous immunoglobulins in sera of mice during aging. J 90. Ahlberg RE, Lefvert AK: Monoclonal gammopathy and antibody activity against the
Immunol 112:2271, 1974. acetylcholine receptor. Am J Hematol 29:49, 1988.
57. Radl J, De Glopper E, Schuit HR, Zurcher C: Idiopathic paraproteinemia: II. Trans- 91. Disdier P, Swiader L, Aillaud M-F, et al: Ig M monoclonal gammopathy, lymphoid pro-
plantation of the paraprotein-producing clone from old to young 57B1/KaLwRij mice. liferations and lupus anticoagulant. Am J Med 102:319, 1997.
J Immunol 122:609, 1979. 92. Dear A, Brennan SO, Sheat MJ, et al: Acquired dysfibrinogenemia caused by monoclo-
58. Radl J: Age-related monoclonal gammopathies: Clinical lessons from the aging C57BL nal production of immunoglobulin lambda light chain. Haematologica 92:e111, 2007.
mouse. Immunol Today 11:234, 1990. 93. Maldonado JE, Velosa JA, Kyle RA, et al: Fanconi syndrome in adults: A manifestation
59. van Arkel C, Hopstaken CM, Zurcher C, et al: Monoclonal gammopathies in aging mu, of a latent form of myeloma. Am J Med 58:354, 1975.
kappa-transgenic mice: Involvement of the B-1 cell lineage. Eur J Immunol 27:2436, 94. Gavarotti P, Fortina F, Costa D, et al: Benign monoclonal gammopathy presenting with
1997. severe renal failure. Scand J Haematol 36:115, 1986.
60. George G, Gilburd B, Schoenfeld Y: The emerging concept of pathogenic natural anti- 95. Maes B, Vanwalleghem J, Kuypers D, et al: IgA antiglomerular basement membrane
bodies. Hum Antibodies 8:70, 1997. disease associated with bronchial carcinoma and monoclonal gammopathy. Am J Kid-
61. Milla F, Oriol A, Aguilar J, et al: Usefulness and reproducibility of cytomorphic evalu- ney Dis 33:E3, 1999.
ations to differentiate myeloma from monoclonal gammopathies of unknown signifi- 96. Hashimoto T, Arakawa K, Ohta Y, et al: Acquired Fanconi syndrome with osteomala-
cance. Am J Clin Pathol 115:127, 2001. cia secondary to monoclonal gammopathy of undetermined significance. Intern Med
62. Rajkumar SV, Mesa RA, Fonesca R, et al: Bone marrow angiogenesis in 400 patients 46:241, 2007.
with monoclonal gammopathy of undetermined significance, multiple myeloma, and 97. Pozzi C, D’Amico M, Fogazzi GB, et al: Light chain deposition disease with renal
primary amyloidosis. Clin Cancer Res 8:2210, 2002. involvement: Clinical characteristics and prognostic factors. Am J Kidney Dis 42:1154,
63. Ludwig H, Vormittag W: “Benign” monoclonal IgE gammopathy. Br Med J 281:539, 2003.
1980. 98. Merlini G, Stone MJ: Dangerous small B-cell clones. Blood 108:2520, 2006.

Kaushansky_chapter 106_p1721-1732.indd 1728 9/21/15 12:40 PM